Related Experiment Video

Updated: Mar 11, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Michael J Kelley1,2,3, Gautam Jha4, Debra Shoemaker2

  • 1a Division of Medical Oncology, Department of Medicine , Duke University Medical Center , Durham , North Carolina , USA.

Cancer Investigation
|December 3, 2016
PubMed

Insights

Dasatinib, a Src inhibitor, showed no activity in advanced non-small cell lung cancer (NSCLC) patients. The drug was also poorly tolerated, with significant toxicity observed in this patient group.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The Src pathway is activated in approximately one-third of non-small cell lung cancer (NSCLC) cases.
  • Dasatinib is known to possess Src-inhibitor activity.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of dasatinib in patients with advanced, previously treated NSCLC.
  • To explore potential RNA biomarkers for treatment response.

Main Methods:

  • A clinical study involving 37 patients with advanced, previously treated NSCLC.
  • Treatment with dasatinib 70 mg twice daily for 25 patients.
  • Pre-treatment biopsies were collected for potential RNA biomarker analysis.

Main Results:

  • No treatment responses were observed in any of the patients.
  • Five patients discontinued dasatinib due to toxicity.
  • Three patients experienced minor biopsy-related pneumothoraces.
  • Biomarker analysis was not performed due to the lack of treatment response.

Conclusions:

  • Dasatinib at 70 mg twice daily demonstrated no clinical activity in unselected patients with advanced, previously treated NSCLC.
  • The drug was not well-tolerated in this patient population, with notable toxicity.
  • Further investigation into Src-inhibitor therapy in NSCLC may require more targeted patient selection.
Keywords:
Non-small cell lung cancerSrcgene expression

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K